In general, across all tumor types, anti-PD-1/PD-L1 therapy results in response rates ranging from 0% to 17% in patients with PD-L1-negative tumors, whereas in those with tumors that express PD-L1, response rates range from 36% to 100% [6]. Here, CD274 is linked to neoplasm.